Axil Capital | Venture Capital

top of page

ENGLISH

日本語

Top

About

Team

Portfolio

Contact

Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical & healthcare technology investments, with emphasis on supporting the growth of early-stage ventures by leveraging our global network and resources.

Axil Capital's Recent News

Mar 31, 2023

The Organization for Small & Medium Enterprises and Regional Innovation, JAPAN (“SMRJ”) announces investment of up to ¥2.0B in ALHF II.

Jan 10, 2023

Axil opens its Technology & Innovation Center.

Nov 9, 2022

Axil Capital Launches its Second Life Science Fund (ALHF II)

Nov 1, 2022

Axil Capital Advisors K.K. announces the appointment of Mr. Yasuto Hamanishi, former Deputy President & Executive Officer Mizuho Securities Co Ltd, as its Executive Advisor as of November 1, 2022.

Jun 28, 2022

Cranebio added to our portfolio companies.

Feb 24, 2022

Angiocrine Bioscience added to our portfolio companies.

Axil Recent News (EN)

Axil Capital's Past News

Portfolio Companies' Recent News

May 15, 2023

Luca Science gave a lecture at the Japan Society of Obstetrics and Gynecology (JSOG) and the presenter, Dr. Yosuke Matsumiya, received the JSOG Congress Award.

May 15, 2023

Perseus Proteomics reported that a Phase I study of PPMX-T003 confirmed the safety and efficacy of the drug in the first three patients treated with the drug.

Apr 19, 2023

Allgenesis Announces Last Patient Enrolled in the Phase 2a Trial Evaluating the Safety and Efficacy of AG-73305 in Diabetic Macular Edema (DME) Patients.

Apr 7, 2023

Himuka AM Pharma has completed a Phase I clinical trial of HM201 in Australia.

Apr 3, 2023

Cranebio presented at a conference on the development of rapid water quality testing in collaboration with Metawater, Co., Ltd.

Mar 31, 2023

Perseus Proteomics Completes PMDA Investigation of Aggressive NK Cell Leukemia Clinical Trial Plan Notification.

Mar 31, 2023

Ricoh Biomedical Startup Fund has decided to invest in United Immunity.

Mar 23, 2023

Jolly Good jointly developed medical VR with Harvard University Hospital to enter the U.S. market.

Mar 16, 2023

United Immunity has published an academic paper on UI-201.

Mar 15, 2023

LUCA Science was selected as one of the 2023 Deep Tech Top 10 by Forbes Japan magazine.

Feb 17, 2023

Suono Bio announces Formulation-Agnostic Platform for the delivery of RNA therapeutics.

Jan 4, 2023

An article on Perseus' Phase I study of PPMX-T003 in healthy subjects was published online in Clinical Pharmacology in Drug Development.

Jan 4, 2023

Suono Bio announces first patient dosed with its SuonoCalm™ Platform.

Dec 19, 2022

TechsoMed Ltd. announces the opening of a new German Subsidiary, as a strategic collaboration with Research Institute Fraunhofer MEVIS.

Dec 19, 2022

Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial.

Dec 10, 2022

LUCA Science presented its research findings at the Annual Meeting of the American Society of Hematology.

Dec 9, 2022

Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology.

Dec 7, 2022

JollyGood has initiated a specific clinical study of digital therapeutic VR for depression with Teijin Pharma.

Nov 28, 2022

Cranebio presented its latest research results on ovulation date prediction at an academic conference in collaboration with Unicharm Corporation.

Oct 24, 2022

TechsoMed Completes Enrollment in United States Pivotal Trial of BioTraceIO Software for Liver Ablation Outcomes Assessment.

Oct 24, 2022

TechsoMed Announces Completion of Full Enrollment in Pivotal U.S trial Evaluating its BioTraceIO Software for Liver Ablation Outcomes Assessment in Liver Cancer Patients.

Oct 10, 2022

Jolly Good has launched FACEDUO, a VR support program for schizophrenia, with Otsuka Pharmaceutical.

Sep 29, 2022

Allgenesis selected as one of the 3 finalists for the Eyecelerator pitch at the American Academy of Ophthalmology conference on September 29, 2022

Aug 4, 2022

The educational effects of the medical education VR developed by Jolly Good and Hiroshima University were published as an article in the American Journal of Infection Control, an American medical journal.

Aug 3, 2022

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 27, 2022

TOP 11 of TAcc+ International Program 2022.

Jul 27, 2022

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors.

Jul 27, 2022

AACR: C4's multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve.

Jun 20, 2022

Allgenesis announces first patient dosed in the U.S. for the Phase 1b trial evaluating AG-80308 for the treatment of dry eye disease.

Jun 13, 2022

Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema.

Jun 8, 2022

LUCA Science was featured in an article in BIOCENTURY.

May 18, 2022

LUCA Science and Kyowa Kirin announce joint research agreement on mitochondrial disease treatment with novel mitochondria modality.

Apr 4, 2022

Research on mice that ‘sweat out’ fat wins STAT Madness for University of Pennsylvania.

Mar 29, 2022

Angiocrine Bioscience announces first patient dosed in pivotal phase 3 clinical trial of AB-205 and completion of Series B financing.

Jun 9, 2022

LUCA Science raised 3.86 billion yen in Series B.

Portfolio Recent News (EN)

Portfolio Companies' Past News

Axil Capital-07.png

【 Head Office 】

Nittochi Nishi-shinbashi Bldg. 7F
1-11-4 Nishi-shinbashi Minato-ku, Tokyo 105-0003, Japan

【 Technology & Innovation Center 】

GLOBAL LIFESCIENCE HUB, Nihombashi Muromachi Mitsui Tower 7F
3-2 Nihombashi Muromachi, Chuo-ku, Tokyo 103-0022

© Axil Capital All Rights Reserved

bottom of page